Dexcom CGM
The Dexcom CGM is a continuous glucose monitoring system developed by Dexcom, Inc., a company specializing in glucose monitoring technology for individuals with diabetes. Several iterations of the Dexcom CGM wearable device have been released, beginning with the Dexcom Short-Term Sensor, followed by the Dexcom Seven and Dexcom Seven Plus. Later models include the Dexcom G4, Dexcom G5, Dexcom G6, and Dexcom G7. The most recently released model, Stelo by Dexcom, is a more affordable option designed for individuals with type 2 diabetes.
Dexcom was founded in 1999 by John Burd and released its first CGM, the Dexcom STS, in 2006 following U.S. Food and Drug Administration approval. As of 2025, only the Dexcom G6, Dexcom G7, and Stelo remain available.
Devices
Early Dexcom CGMs
The Dexcom Short-Term Sensor, commonly abbreviated as STS, was a three-day continuous glucose monitor designed to provide real-time glucose readings to assist individuals with type 1 diabetes in managing their blood sugar levels. The STS received approval from the FDA in March 2006.The STS was considered valuable for trend information, but not sufficiently accurate for insulin dosage decisions. The original STS was discontinued in 2007 and 2008 following the release of an improved device, the Dexcom Seven.
The STS-7, better known as the Dexcom Seven, that was introduced to the market in 2007, was the first CGM system to provide a full seven-day wear time, reducing the frequency of sensor changes. Before the introduction of the Dexcom Seven, the company's primary research and development efforts had been focused on creating a fully implantable glucose sensor that could function continuously for periods ranging from one month to an entire year.
The Dexcom Seven Plus, the successor to the original Dexcom Seven, was released in 2010 after obtaining FDA approval earlier that year. The Seven Plus featured improvements in accuracy, and introduced low and high blood sugar alarms, enhancing the system's ability to alert users to potential hypoglycemia and hyperglycemia. Dexcom marketed the Seven Plus as the "GPS of the CGM world." Both the Dexcom Seven and the Dexcom Seven Plus were eventually rendered obsolete and had their FDA approvals withdrawn in 2015 as newer and more advanced Dexcom fCGM systems became available.
"New generation" Dexcom CGMs
In 2012, Dexcom received regulatory approval for the Dexcom G4 Platinum, commonly referred to as the Dexcom G4. This device introduced several aesthetic customization options, including various color choices for the G4 receiver; featured an expanded wireless transmission range of up to twenty feet without obstruction—an improvement over previous continuous glucose monitors; and, had improved accuracy, especially during hypoglycemic episodes. In 2014, the G4 was approved for pediatric use, thereby extending its applicability to younger patients.In 2015, the Dexcom G5 was introduced. The G5 provided blood glucose readings at five‐minute intervals and was the first device in the Dexcom CGM series to offer direct compatibility with a mobile application. This advancement allowed users to view glucose data on their smartphones, share information via the Dexcom Share app, and track long‐term trends using the Dexcom Clarity app. Both the Dexcom G4 Platinum and the Dexcom G5 were discontinued at the end of 2020.
Modern CGMs
In 2018, the FDA approved the Dexcom G6 for use as a stand-alone CGM, and for integration with compatible insulin pumps, making it the first continuous glucose monitor capable of direct integration with insulin pumps. The G6 was also the first CGM to operate without the need for calibrations, removing the requirement for routine fingerstick blood tests. However, actual blood glucose levels can differ from the levels reported by the CGM. The device retained compatibility with Dexcom's existing mobile applications, including Dexcom Share, which allows users to share glucose data with others, and Dexcom Clarity, which provides long-term trend analysis and reports. As of 2025, the Dexcom G6 remains available.Unofficial Modification: Dexcom Anubis
The Dexcom Anubis is an unofficial, modified transmitter for the Dexcom G6 continuous glucose monitoring system, developed by a community of developers. It is not a product of Dexcom, Inc. The modification involves hardware and firmware changes to the standard G6 transmitter, primarily to allow for a user-replaceable battery and to bypass the 110-day transmitter hard-stop, effectively granting it an indefinite operational lifespan.The primary motivations for its use are to reduce the long-term cost of CGM ownership by reusing hardware and to enable extended sensor sessions. The Anubis firmware allows for a reduced sensor warm-up period of 50 minutes and permits a single sensor session to last up to 60 days, far beyond the factory-limited 10 days. The Anubis transmitter remains compatible with the official Dexcom G6 mobile application and receiver, as well as with automated insulin delivery systems that integrate with the G6.
A dedicated mobile application is used to manage the transmitter's features, including checking the battery level, resetting the transmitter's life counter, and toggling between its extended and default parameters.
Using the Anubis transmitter or similar modifications voids the manufacturer's warranty on Dexcom equipment. Dexcom states that sensor performance and accuracy cannot be guaranteed beyond the approved wear duration, and the company does not support the use of modified hardware. The Anubis project is a prominent example of a user-driven "do-it-yourself" solution within the diabetes technology community.
Dexcom G7 and Stelo
The Dexcom G7 brought several design and functionality changes, receiving multiple design awards for its updated form factor and features. The G7 introduced direct smartwatch connectivity, making it the first Dexcom CGM compatible with the Apple Watch without requiring an intermediary smartphone connection. In addition, while previous Dexcom CGMs were compatible only with Tandem insulin pumps, the G7 expanded its integration to include the Omnipod 5 system.The G7 was first released in the United Kingdom, Ireland, Germany, Austria, and Hong Kong in October 2022. In December 2022, the G7 received FDA approval, with availability in the United States beginning in February 2023. The G7's launch was promoted through a Super Bowl advertisement featuring Nick Jonas, a singer with type one diabetes who is a G7 user.
On March 5, 2024, the Dexcom G7 15-Day Continuous Glucose Monitoring System was approved by the U.S. Food and Drug Administration for individuals aged 18 years and older with diabetes. This version of the G7 extends the sensor wear time from 10.5 to 15.5 days and features a slightly improved mean absolute relative difference of 8.0%, compared to the original G7’s 8.2%. The system provides real-time glucose readings every five minutes via the Dexcom G7 app and includes a 12-hour grace period for sensor replacement.
In the summer of 2024, Dexcom introduced Stelo by Dexcom, a CGM similar to the G7 but with modified features and alarm settings. Stelo is intended for adult individuals who do not require insulin therapy or frequent low blood sugar alerts, differentiating it from other Dexcom CGMs designed for insulin-dependent users. Unlike other Dexcom models, Stelo is available over the counter and does not require a prescription. As of December 1, 2025, both the Dexcom G7 15-Day; G7 and Stelo are available in the U.S. market, only the G7 and Stelo are available internationally.
Components
Each generation of the Dexcom CGM system has consisted of two primary components: the sensor and the transmitter. The sensor is a thin wire that is inserted into the subcutaneous tissue, where it measures interstitial glucose levels. The transmitter is a small electronic device that attaches to the sensor and wirelessly transmits the glucose data to a compatible receiver, smartphone, or other monitoring device, allowing users to view their glucose readings in real time. The Dexcom G7 was the first Dexcom CGM to have an all-in-one sensor and transmitter. In addition to the sensor and transmitter, Dexcom CGM systems also include an applicator, which is the device used to insert the sensor into the tissue. Blood glucose readings are viewed on a device-specific receiver or modern systems via a smartphone application.Sensor
The Dexcom sensor operates as an implantable electrochemical device that continuously measures glucose levels in the interstitial fluid beneath the skin. It consists of a non-conductive body housing three electrodes: a working electrode that reacts with glucose, a reference electrode that maintains a constant voltage, and a counter electrode that completes the electrical circuit. The counter electrode is designed with a larger reactive surface area to enhance measurement accuracy. These components are inserted into the subcutaneous tissue using an applicator. A multi-layer membrane covers the electrodes, regulating the diffusion of substances to the sensor and promoting stable, reliable readings. The resulting electrical signal is transmitted by the Dexcom transmitter to a compatible receiver or smart device for real-time glucose monitoring.Until the release of the Dexcom G7 and Stelo, the sensor and transmitter were separate components, with the transmitter snapping into the sensor. However, the G7 and Stelo models integrate both the sensor and transmitter into a single, disposable system.